Altimmune, Inc. (ALT)
Automate Your Wheel Strategy on ALT
With Tiblio's Option Bot, you can configure your own wheel strategy including ALT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ALT
- Rev/Share 0.0003
- Book/Share 1.8818
- PB 1.9184
- Debt/Equity 0.0
- CurrentRatio 15.8463
- ROIC -0.6609
- MktCap 292796270.0
- FreeCF/Share -1.0633
- PFCF -3.6449
- PE -3.0222
- Debt/Assets 0.0
- DivYield 0
- ROE -0.6544
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ALT | William Blair | -- | Market Perform | -- | -- | Feb. 28, 2025 |
| Initiation | ALT | Stifel | -- | Buy | -- | $18 | Jan. 8, 2025 |
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
Published: June 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Altimmune's Fatty Liver Candidate Faces Differentiation Doubts
Published: June 27, 2025 by: Benzinga
Sentiment: Negative
On Thursday, Altimmune, Inc. ALT released topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH).
Read More
Altimmune: FDA Path Forward Remains Despite Mixed MASH Treatment Data Of Pemvidutide
Published: June 26, 2025 by: Seeking Alpha
Sentiment: Positive
Altimmune, Inc.'s pemvidutide met the primary endpoint of MASH resolution in phase 2b IMPACT study which sets it on a continued development path going forward. The short 24-week trial duration likely limited fibrosis results; longer studies could achieve statistical significance with this endpoint supporting a continued path for phase 3 development. Pemvidutide uniquely delivers both MASH resolution and weight loss, with the lowest adverse event-related discontinuation rates, giving it strong competitive advantages.
Read More
INVESTOR ALERT: Investigation of Altimmune, Inc. (ALT) Announced by Holzer & Holzer, LLC
Published: June 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, June 26, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) complied with federal securities laws. On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH), revealing that the trial did not demonstrate statistical significance for the endpoint of improving fibrosis while not worsening MASH. Following this news, the price of the Company's stock dropped.
Read More
Altimmune shares plunge as MASH drug trial misses key fibrosis endpoint
Published: June 26, 2025 by: Proactive Investors
Sentiment: Negative
Shares of Altimmune Inc (NASDAQ:ALT) tumbled 55% on Thursday after the company reported mixed results from a mid-stage trial of its experimental drug pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH). The Phase 2b study met one of its primary endpoints, with pemvidutide achieving statistically significant resolution of MASH without worsening of fibrosis at 24 weeks.
Read More
Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential
Published: June 02, 2025 by: Seeking Alpha
Sentiment: Positive
I rate Altimmune a 'Strong Buy' and Viking Therapeutics a 'Buy' for high-risk, long-term investors. ALT's Pemvidutide stands out for its lean mass protection, visceral fat reduction, and potential in multiple metabolic diseases, making it an attractive acquisition target. VKTX's VK2735 offers strong weight loss efficacy and dual formulation flexibility, but faces tough competition and lacks clear differentiation, despite financial stability.
Read More
Altimmune: Upcoming MASH Data Could Be High Impact For Business Development Activity
Published: May 29, 2025 by: Seeking Alpha
Sentiment: Positive
ALT is approach a readout from IMPACT, a phase 2b study of pemvidutide in MASH. MDGL's results with its launch of MASH drug Rezdiffra demonstrate the multi-billion-dollar potential of a MASH drug, although pemvidutide will be compared to other competitors. ALT has also initiated a trial of pemvidutide in alcohol use disorder, with a trial in alcohol liver disease set to start in Q3'25.
Read More
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first subject in the RECLAIM Phase 2 trial evaluating the efficacy and safety of pemvidutide in subjects with Alcohol Use Disorder (AUD). Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, AUD and alcohol liver disease (ALD). IMPACT, a Phase 2b trial of pemvidutide in MASH, is expected to read out topline data in the second …
Read More
Altimmune, Inc. (ALT) Q1 2025 Earnings Call Transcript
Published: May 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Altimmune, Inc. (NASDAQ:ALT ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Lee Roth - President, Burns McClellan, Investor Relations Advisors Vipin Garg - Chief Executive Officer Scott Harris - Chief Medical Officer Greg Weaver - Chief Financial Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Liisa Bayko - Evercore Roger Song - Jefferies Annabel Samimy - Stifel Mayank Mamtani - B Riley Andy Hsieh - William Blair Operator Good day, ladies and gentlemen, and welcome to Altimmune First Quarter 2025 Financial Results Conference Call. After the speakers' …
Read More
How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86%
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Altimmune (ALT) points to a 285.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
MASH Resolution Index (MASHResInd) model highly predictive of MASH resolution MASH Resolution Index (MASHResInd) model highly predictive of MASH resolution
Read More
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 13, 2025.
Read More
Altimmune to Present at Upcoming EASL International Liver Congress™ 2025
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
GAITHERSBURG, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced that the Company will present analyses of pemvidutide-treated subjects with metabolic dysfunction-associated steatotic liver disease (MASLD) utilizing the MASH Resolution Index (MASHResInd; Loomba 2024), a highly sensitive non-invasive measure of MASH histologic response, in a poster session at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2025 in Amsterdam, The Netherlands. The abstract will be featured in the conference poster session and poster tour.
Read More
Altimmune to Participate in the Citizens Life Sciences Conference
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate in a fireside chat at the Citizens Life Sciences Conference. Details are as follows:
Read More
Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Positive
Altimmune's pemvidutide shows promise in treating MASH with obesity, potentially positioning it as a first-in-class drug targeting both liver health and weight loss. Despite past volatility, ALT stock has stabilized, with recent data showing significant weight loss at higher doses, sparking renewed investor interest. Altimmune's Q4 2024 earnings reveal a net loss of $23.2m, with $131.9m in cash, highlighting the company's ongoing financial challenges and reliance on future clinical success.
Read More
Altimmune, Inc. (ALT) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Altimmune, Inc. (NASDAQ:ALT ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Lee Roth - President, Burns McClellan, Investor Relations Advisors Vipin Garg - Chief Executive Officer Scott Harris - Chief Medical Officer Greg Weaver - Chief Financial Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Annabel Samimy - Stifel Liisa Bayko - Evercore William Wood - B. Riley Securities Jonathan Wolleben - Citizens JMP Patrick Trucchio - H.C.
Read More
Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025 Investigational New Drug (IND) applications in two additional indications have received FDA clearance, with Phase 2 trials to commence mid-2025 Company to hold virtual R&D Day on March 13, 2025. Program will include KOL presentations on pemvidutide development in obesity, MASH and additional indications Two pharmaceutical industry veterans added to Company Board of Directors Cash, cash equivalents and short-term investments of $131.9 million on December 31, 2024 Webcast to be held today, February 27, 2025, at 8:30 a.m.
Read More
Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH
Published: February 18, 2025 by: Seeking Alpha
Sentiment: Positive
Altimmune is a single-molecule company currently trading at a $0.5 billion market cap with a favorable risk-reward profile. The company's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH (metabolic dysfunction-associated steatohepatitis). Pemvidutide has successfully completed a Phase 1 trial for a related liver disease but has yet to demonstrate efficacy in the target indication of MASH.
Read More
About Altimmune, Inc. (ALT)
- IPO Date 2017-05-26
- Website https://altimmune.com
- Industry Biotechnology
- CEO Vipin K. Garg
- Employees 59